艾曲泊帕在免疫性血小板减少症和获得性特发性再生障碍性贫血中的疗效：单中心经验
Response of Eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia: A single-center experience.
作者信息
Abbasi Abdul Muqtadir, Shaikh Mohammad Usman, Ali Natasha, Khan Maria, Soomar Salman Muhammad
机构信息
Department of Oncology, Aga Khan University Karachi Pakistan.
Department of Pathology & Laboratory Medicine, Aga Khan University Karachi Pakistan.
出版信息
Leuk Res Rep. 2022 Feb 16;17:100295. doi: 10.1016/j.lrr.2022.100295. eCollection 2022.
Eltrombopag has been used in ITP and found its use in AA armamentarium recently. We retrospectively analyzed 61 patients at a tertiary care center in Pakistan from January 2015 to January 2021. They included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.
艾曲泊帕已用于治疗免疫性血小板减少症（ITP），最近还被纳入再生障碍性贫血（AA）的治疗药物中。我们对巴基斯坦一家三级医疗中心2015年1月至2021年1月期间的61例患者进行了回顾性分析。这些患者包括对至少一个疗程免疫抑制治疗无效的重型AA患者，以及既往至少接受过一次ITP治疗的持续性/慢性ITP患者。在我们的研究人群中，艾曲泊帕的疗效与实际临床经验相当，同时值得注意的是，其肝毒性和胃肠道问题在可耐受范围内。我们发现艾曲泊帕是一种治疗ITP和AA患者安全有效的药物。
Zotero 插件